Key result
Flecainide has recently been added to the therapeutic arsenal for the treatment of catecholaminergic polymorphic ventricular tachycardia, supplementing beta-blockers.
Why the study?
Does flecainide improve outcomes in patients with Catecholaminergic polymorphic ventricular tachycardia?
Does flecainide improve outcomes in patients with Catecholaminergic polymorphic ventricular tachycardia?
This review summarizes the current evidence on the efficacy and role of flecainide as an addition to beta-blockers in the management of catecholaminergic polymorphic ventricular tachycardia.
Supports adjunctive flecainide in CPVT; leaves open need for randomized trials before practice change.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but severe genetic cardiac arrhythmia disorder, with symptoms including syncope and sudden cardiac death due to polymorphic VT or ventricular fibrillation typically triggered by exercise or emotions in the absence of structural heart disease. The cornerstone of medical therapy for CPVT is β-blockers. However, recently flecainide has been added to the therapeutic arsenal for CPVT. In this review we summarise current data on the efficacy and role of flecainide in the treatment of CPVT.
No takes yet. Share an insight, caveat, or question.
Lieve et al. (2016) conducted a review in Catecholaminergic polymorphic ventricular tachycardia (CPVT). Flecainide was evaluated. Flecainide has recently been added to the therapeutic arsenal for the treatment of catecholaminergic polymorphic ventricular tachycardia, supplementing beta-blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: